## Giuseppe Penna

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8873005/giuseppe-penna-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80 76 9,317 47 h-index g-index citations papers 80 10,651 8.5 5.9 L-index avg, IF ext. papers ext. citations

#	Paper	IF	Citations
76	Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 <b>2021</b> , 9,		4
75	Identification of a choroid plexus vascular barrier closing during intestinal inflammation. <i>Science</i> , <b>2021</b> , 374, 439-448	33.3	21
74	Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. <i>Cancer Cell</i> , <b>2021</b> , 39, 708-724.e11	24.3	34
73	Functional characterization and immunomodulatory properties of Lactobacillus helveticus strains isolated from Italian hard cheeses. <i>PLoS ONE</i> , <b>2021</b> , 16, e0245903	3.7	1
72	Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. <i>Cell Reports</i> , <b>2021</b> , 36, 109312	10.6	2
71	Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. <i>Nature Microbiology</i> , <b>2020</b> , 5, 511-524	26.6	104
70	Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1216-1228	13.4	163
69	Genomic diversity and immunomodulatory activity of Lactobacillus plantarum isolated from dairy products. <i>Beneficial Microbes</i> , <b>2017</b> , 8, 597-604	4.9	8
68	Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. <i>Nature Communications</i> , <b>2016</b> , 7, 11037	17.4	126
67	The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. <i>Nature Medicine</i> , <b>2016</b> , 22, 624-31	50.5	145
66	Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 413-22	11.5	75
65	BALB/c and C57BL/6 Mice Differ in Polyreactive IgA Abundance, which Impacts the Generation of Antigen-Specific IgA and Microbiota Diversity. <i>Immunity</i> , <b>2015</b> , 43, 527-40	32.3	188
64	The immune system in the control of microbiota homeostasis. Italian Journal of Pediatrics, 2015, 41,	3.2	78
63	A gut-vascular barrier controls the systemic dissemination of bacteria. <i>Science</i> , <b>2015</b> , 350, 830-4	33.3	269
62	Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1+ macrophages to CD103+ dendritic cells. <i>Immunity</i> , <b>2014</b> , 40, 248-61	32.3	306
61	Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo. <i>PLoS ONE</i> , <b>2014</b> , 9, e87615	3.7	62
60	Dendritic Cell Modulation by the Vitamin D System <b>2012</b> , 103-125		

## (2007-2012)

59	Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. <i>Gut</i> , <b>2012</b> , 61, 1007-15	19.2	209
58	Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. <i>Gut</i> , <b>2011</b> , 60, 463-72	19.2	426
57	Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. <i>Annals of the New York Academy of Sciences</i> , <b>2010</b> , 1193, 146-52	6.5	46
56	Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. Journal of Endocrinological Investigation, <b>2010</b> , 33, 730-8	5.2	9
55	Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. <i>Journal of Developmental and Physical Disabilities</i> , <b>2010</b> , 33, 475-88		140
54	Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. <i>Immunology Letters</i> , <b>2010</b> , 131, 49-58	4.1	58
53	Prostate autoimmunity: from experimental models to clinical counterparts. <i>Expert Review of Clinical Immunology</i> , <b>2009</b> , 5, 577-86	5.1	23
52	Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. <i>Journal of Immunology</i> , <b>2009</b> , 182, 4056-64	5.3	121
51	The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. <i>Prostate</i> , <b>2009</b> , 69, 480-93	4.2	76
50	Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. <i>Human Immunology</i> , <b>2009</b> , 70, 345-52	2.3	150
49	Induction of tolerogenic dendritic cells by vitamin D receptor agonists. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> , 251-73	3.2	74
48	Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3. <i>Journal of Medicinal Chemistry</i> , <b>2009</b> , 52, 220	8.3 4-13	32
47	Control of autoimmune diseases by the vitamin D endocrine system. <i>Nature Clinical Practice Rheumatology</i> , <b>2008</b> , 4, 404-12		377
46	Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells. <i>Journal of Bone and Mineral Research</i> , <b>2007</b> , 22 Suppl 2, V69-73	6.3	26
45	Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. <i>European Urology</i> , <b>2007</b> , 51, 524-33; discussion 533	10.2	216
44	Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. <i>Journal of Immunology</i> , <b>2007</b> , 179, 1559-67	5.3	43
43	Vitamin D receptor agonists as anti-inflammatory agents. <i>Expert Review of Clinical Immunology</i> , <b>2007</b> , 3, 477-89	5.1	13
42	1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. <i>Journal of Immunology</i> , <b>2007</b> , 178, 145-53	5.3	264

41	Calcitriol derivatives with two different side chains at C-20 III. An epimeric pair of the gemini family with unprecedented antiproliferative effects on tumor cells and renin mRNA expression inhibition. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 277-81	5.1	19
40	Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2007</b> , 103, 689-93	5.1	70
39	Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. <i>Methods in Molecular Biology</i> , <b>2007</b> , 380, 285-311	1.4	47
38	Vitamin D receptor agonists, cancer and the immune system: an intricate relationship. <i>Current Topics in Medicinal Chemistry</i> , <b>2006</b> , 6, 1297-301	3	23
37	Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. <i>Journal of Immunology</i> , <b>2006</b> , 177, 8504-11	5.3	99
36	Leukocyte migration to pancreatic islets: a critical step in the pathogenesis of type 1 diabetes <b>2006</b> , 16	7-179	1
35	Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. <i>Blood</i> , <b>2005</b> , 106, 3490-7	2.2	304
34	Manipulating dendritic cells to induce regulatory T cells. <i>Microbes and Infection</i> , <b>2005</b> , 7, 1033-9	9.3	35
33	Exploiting the potential of regulatory T cells in the control of type 1 diabetes <b>2005</b> , 95-109		
32	Human immunodeficiency virus type 1 gp120 and other activation stimuli are highly effective in triggering alpha interferon and CC chemokine production in circulating plasmacytoid but not myeloid dendritic cells. <i>Journal of Virology</i> , <b>2005</b> , 79, 12597-601	6.6	42
31	A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. <i>Journal of Immunology</i> , <b>2004</b> , 173, 2280-	7 <sup>5.3</sup>	154
30	Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. <i>Seminars in Immunology</i> , <b>2004</b> , 16, 127-34	10.7	159
29	Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2004</b> , 89-90, 437-41	5.1	150
28	IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma. <i>Journal of Immunology</i> , <b>2003</b> , 170, 5491-501	5.3	74
27	Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. <i>Journal of Cellular Biochemistry</i> , <b>2003</b> , 88, 227-3	<b>3</b> 4·7	170
26	Unique regulation of CCL18 production by maturing dendritic cells. <i>Journal of Immunology</i> , <b>2003</b> , 170, 3843-9	5.3	134
25	Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. <i>Journal of Neuroimmunology</i> , <b>2002</b> , 130, 10-21	3.5	86
24	Polymorphisms in the Il12b gene affect structure and expression of IL-12 in NOD and other autoimmune-prone mouse strains. <i>Genes and Immunity</i> , <b>2002</b> , 3, 151-7	4.4	28

23	Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells. <i>Journal of Immunology</i> , <b>2002</b> , 169, 6673-6	5.3	163
22	Thiol antioxidants inhibit the formation of the interleukin-12 heterodimer: a novel mechanism for the inhibition of IL-12 production. <i>Cytokine</i> , <b>2002</b> , 17, 285-93	4	16
21	Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. <i>Human Immunology</i> , <b>2002</b> , 63, 1164-71	2.3	193
20	IL-12 administration reveals diabetogenic T cells in genetically resistant I-Ealpha-transgenic nonobese diabetic mice: resistance to autoimmune diabetes is associated with binding of Ealpha-derived peptides to the I-A(g7) molecule. <i>Journal of Immunology</i> , <b>2001</b> , 167, 4104-14	5.3	12
19	Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. <i>Human Gene Therapy</i> , <b>2001</b> , 12, 905-20	4.8	52
18	Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. <i>Journal of Immunology</i> , <b>2001</b> , 167, 1821-9	5.3	156
17	Induction of transplantation tolerance by 1,25-dihydroxyvitamin D(3). <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 58-9	1.1	9
16	Inhibition of costimulatory pathways for T-cell activation by 1,25-dihydroxyvitamin D(3). <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 2083-4	1.1	13
15	Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. <i>Journal of Immunology</i> , <b>2001</b> , 167, 1862-6	5.3	272
14	The control of T cell responses by dendritic cell subsets. <i>Current Opinion in Immunology</i> , <b>2000</b> , 12, 114-2	<b>1</b> 7.8	194
13	Early Th1 response in unprimed nonobese diabetic mice to the tyrosine phosphatase-like insulinoma-associated protein 2, an autoantigen in type 1 diabetes. <i>Journal of Immunology</i> , <b>2000</b> , 165, 6748-55	5.3	35
12	Functional maturation of adult mouse resting microglia into an APC is promoted by granulocyte-macrophage colony-stimulating factor and interaction with Th1 cells. <i>Journal of Immunology</i> , <b>2000</b> , 164, 1705-12	5.3	125
11	1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. <i>Journal of Immunology</i> , <b>2000</b> , 164, 2405	-∮1³	1014
10	The involvement of IL-12 in murine experimentally induced autoimmune thyroid disease. <i>European Journal of Immunology</i> , <b>1999</b> , 29, 1933-42	6.1	34
9	Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1/Th2 cell restimulation. <i>European Journal of Immunology</i> , <b>1999</b> , 29, 2705-14	6.1	107
8	CD40-CD154 interaction and IFN-gamma are required for IL-12 but not prostaglandin E2 secretion by microglia during antigen presentation to Th1 cells. <i>Journal of Immunology</i> , <b>1999</b> , 162, 1384-91	5.3	67
7	A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes. <i>Journal of Immunology</i> , <b>1999</b> , 162, 6630-40	5.3	9
6	Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice. Journal of Immunology, <b>1999</b> , 163, 2960-8	5.3	59

5	Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. <i>European Journal of Immunology</i> , <b>1998</b> , 28, 2003-16	6.1	68
4	Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. <i>Journal of Experimental Medicine</i> , <b>1997</b> , 185, 317-28	16.6	717
3	Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. <i>European Journal of Immunology</i> , <b>1997</b> , 27, 2330-9	6.1	112
2	Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. <i>Journal of Experimental Medicine</i> , <b>1995</b> , 181, 817-21	16.6	404

Dendritic Cell Manipulation with Biological and Pharmacological Agents to Induce Regulatory T Cells545-567